Customer Service: 866-788-9007
Screenshot (4)

Cutaneous Melanoma: A Focus on our Patients

In July of 2021, 31-year-old Morgan England noticed a spot on her arm that didn’t look like it used to. Following her next routine dermatology appointment her world began to change. Morgan’s story underscores the importance of being an advocate for your own health. 

Recent Survey in Collaboration with the Melanoma Research Foundation Indicates that 9 out of 10 Patients with Melanoma Desire Prognostic Testing

A recent publication in Cancer Medicine entitled “Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test,” evaluated patients' attitudes toward prognostic testing and assessed if patients who had received GEP testing experienced decision regret.


Key Takeaways:

  • 90% of patients with melanoma desired prognostic testing
  • Of patients that did not receive 31-GEP testing, 54% wished they had been offered the option
  • Patients receiving 31-GEP results did not experience decision regret, even among patients who
    had Class 2, high-risk tumors
  • Patients receiving 31-GEP results expressed numerous reasons they desired prognostic testing
    including: increased knowledge and understanding, reduction of anxiety about the future,
    information relevant to life planning, and potential for more personalized treatment options.
Scroll to Top
Scroll to Top